Vaccine Stabilizer

The present invention relates to liquid and lyophilized viral vaccines. More particularly it relates to a stabilizer for liquid and lyophilized viral vaccines.

Due to the worldwide distribution of vaccines and the diversity of ambient temperatures, there has been a need to stabilize these preparations for transportation and use. Several stabilization methods have been used in the past.

(A) Low temperatures (-10.degree. C. to -70.degree. C.). The need for low temperature storage facilities which are not always available limits the practicality of this approach.

(B) Lyophilization Although lyophilization suffers the disadvantages of being an expensive procedure, lyophilized vaccines are reasonably stable and are stored at 4.degree.-8.degree. C. until needed. During this storage period, however, the vaccines slowly deteriorates until after about 12-24 months it does not have sufficient titer to confer immunization. Furthermore, since the lyophilized vaccine must be reconstituted prior to use, the liquid reconstituted preparation loses potency while standing at room temperature. This can result in insufficient titer to confer immunity and results in failure of immunization program.

(C) Stabilizers These are chemical compounds added to the vaccine and are used in conjunction with either lower temperature storage or lyophilization methods. While chemical stabilizers, e.g., MgSO.sub.4, SPGA (a stabilizer described by Bovarnick et al., J. Bact. 59:509-522 (1950), the disclosure of which is incorporated herein by reference) and the like are described in the prior art, none imparts the desired enhanced sustained level of stability. The mixture contained 0.218 M sucrose, 0.0038 M monopotassium phosphate, 0.0072 M dipotassium phosphate, 0.0049 M monosodium glutamate, and 1% bovine albumin powder) and the like are described in the prior art, none imparts the desired enhanced sustained level of stability.

It is, accordingly, an object of the present invention to provide an improved chemical stabilizer for lyophilized and liquid viral vaccines.

Another object is to provide a method for stabilizing lyophilized and liquid viral vaccines.

A further object is to provide lyophilized and liquid viral vaccines having prolonged storage stability with diminished reduction in titer.

These and other objects of the present invention will be apparent from the following description.

An improved stabilized liquid or lyophilized live viral vaccine contains a live virus, partially hydrolyzed gelatin, a 6-carbon polyhydric alcohol, a cell culture medium, and sufficient physiologically acceptable acidic buffer to maintain the pH at 6.0-6.5.

The present invention is directed to a stabilized vaccine composition in lyophilized or liquid form containing a live virus, partially hydrolyzed gelatin, a 6-carbon polyhydric alcohol, a cell culture medium and sufficient physiologically acceptable acidic buffer to maintain the pH at from about 6.0 to about 6.5. Examples of live virus are measles, mumps or rubella, varicella, polio, or hepatitis and the like, or a combination of any two or more of such viruses. Hydrolyzed gelatin is employed to provide a soluble, nongelling proteinaceous matrix with little or no pyrogenicity or antigenicity.

By partially hydrolyzed gelatin is meant gelatin which has been subjected to partial hydrolysis to yield a partially hydrolyzed gelatin having a molecular weight of about 3,000. This gelatin hydrolysis product has approximately the same amino acid composition as gelatin. Unlike gelatin which forms gels but is insoluble in cold water, hydrolyzed gelatin does not gel but is soluble in cold water, and other common liquids such as milk and orange juice. Aqueous solutions containing up to about 10% hydrolyzed gelatin do not increase appreciably in viscosity. Above about 10% concentration, viscosity increases slowly. At about 50% concentration, solutions are quite viscous. The typical amino-acid composition of hydrolyzed gelatin follows:

Partially hydrolyzed gelatin may be obtained by enzymatic hydrolysis of gelatin by means of a proteolytic enzyme, such as, for example, papain, chymopapain and bromelin, although other known hydrolysis means may be employed, e.g. acid hydrolysis. A suitable hydrolyzed gelatin is obtainable from Wilson and Co., Inc., Calumet City, Illinois under the trade name SOL-U-PRO. The 6-carbon polyhydric alcohol may be, for example, sorbitol, mannitol or dulcitol. Sorbitol is preferred.

The acidic buffer may be any physiologically acceptable buffer which will maintain the desired pH of from about 6 to about 6.5, for example, phosphate buffer, acetate buffer or citrate buffer. Phosphate buffer is preferred. The stabilizer is diluted with from about 3 to about 8 times, preferably about 5.5 times, its weight of distilled water before use.

By a cell culture medium is meant a nutrient medium which permits growth of cells in vitro. Some specific nutrient media are, for example, Medium 199, Morgan et al., Proc. Soc. Exp. Biol. & Med., 73:1-8, 1950; Basal Medium Eagle, Eagle, Science, 122, 501-504, 1955; In Vitro, Vol. 6, No. 2, 1970; Dulbecco's Modified Eagle's Medium, Dulbecco et al., Virology, 8, 396, 1959; Smith et al., J. Virol., 12, 185-196, 1960; In Vitro, Vol. 6, No. 2, 1970; Minimum Essential Medium (Eagle), Science, 130, 432 (1959) and RPMI Media, Moore et al., 199, 519-524, 1967; In Vitro, Vol. 6, No. 2, 1970.

The stabilizer composition of the present invention contains the following ingredients in about the amounts indicated:

With a liquid vaccine sorbitol is generally present in an amount toward the upper end of the range, while with a lyophilized vaccine sorbitol is generally present in an amount toward the lower end of the range.

Specific formulations for the viral vaccine stabilizer of the present invention follow. Formulation B is preferred for a lyophilized vaccine.

In addition the stabilizer optionally but preferably contains a small amount of NaHCO.sub.3 and of phenol red. In the case of the foregoing formulation the NaHCO.sub.3 may be present in an amount of about 1.2 g and the phenol red in an amount of about 0.01 g. While particular formulations have been described above it is to be understood that variations in ratios and concentration of each ingredient are contemplated. One volume of bulk vaccine is usually diluted with from about 2 to about 12 volumes of stabilizer.

The following examples illustrate the present invention without, however, limiting the same thereto.

80 Ml. of measles viral concentrate which has been stored at -70.degree. is thawed in a water bath at 25.degree. C. and then kept at 4.degree.-8.degree.. The liquid viral concentrate is then split into two aliquots each 40 ml.

(a) One 40 ml aliquot from this virus fluid is diluted in 210 ml of the previously described sterile stabilizer of formulation B. Formulation is carried on under aseptic conditions and laminar flow hood. To prevent microbial growth 10.5 mg. Neomycin are added to the preparation. The diluted vaccine is dispensed into 2 ml glass ampules (0.7 ml vaccine per ampule) which are immediately flame sealed and stored at 4.degree.-8.degree. C.

(b) The second 40 ml aliquot is handled as the first, except that, instead of the stabilizer of formulation B, a standard commercial vaccine diluent (SPGA) is used. The storage stability of the vaccines is described in the following table:

32 Ml. of measles viral concentrate which has been stored at -70.degree. is thawed in a water bath at 25.degree. C. and then kept at 4.degree.-8.degree.. The liquid viral concentrate is then split into two aliquots each 16 ml.

(a) One 16 ml aliquot from this virus fluid is diluted in 48 ml of the previously described sterile stabilizer of formulation B. Formulation is carried on under aseptic conditions and laminar flow hood. To prevent microbial growth 2.5 mg Neomycin are added to the preparation. The diluted vaccine is dispensed into 2 ml glass ampules (0.7 ml vaccine per ampule) which are immediately flame sealed and stored at 37.degree. C.

(b) The second 16 ml aliquot is handled as the first, except that, instead of the stabilizer of formulation B, the stabilizer of formulation A is used. The storage stability of the vaccines is described in the following table:

80 Ml. of measles viral concentrate which has been stored at -70.degree. C. is thawed in a water bath at 20.degree. C. and then kept at 4.degree.-8.degree. C. The liquid viral concentrate is split into two parts of 40 ml each.

(a) One 40 ml aliquot from ths virus fluid is diluted in 210 ml of the previously described sterile stabilizer of formulation B. Formulation is carried on under aseptic conditions and laminar flow hood. To prevent microbial growth 10.5 mg Neomycin are added to the preparation. The diluted vaccine is dispensed into 3 ml glass vials (0.7 vaccine per vial) which are lyophilized, stoppered and stored at 37.degree. C.

(b) The second 40 ml viral aliquot is handled as the first one, except that, instead of the stabilizer of formulation B, a standard commercial diluent (Medium 199 containing SPGA) is used.

The storage stability of these vaccines is described in the following table:

Lyophilized vials prepared as in Example 3 are reconstituted in distilled water (0.7 ml per vial) and stored at 2.degree.-8.degree. C.

The storage stability of these vaccines is described in the following table: